ArticleCancer causes & control : CCC2025
Cancer, HIV, and stigma: a portfolio analysis of grants funded by the National Cancer Institute.
Article in Cancer causes & control : CCC, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
purposePeople with HIV (PWH) are at higher risk of cancer compared to the general population and experience worse cancer outcomes compared to cancer patients without HIV. One contributing factor to these outcomes is stigma, a social phenomenon that manifests across both HIV and cancer and compounds among those with a dual diagnosis. To assess the state of research, we conducted a portfolio analysis of National Cancer Institute (NCI)-funded extramural grants on this topic.
methodsA keyword search identified 47 potentially relevant awards funded between Fiscal Years 2014-2024. Sixteen awards (8 research awards; 8 grant supplements) met inclusion criteria and were further double-coded for key study characteristics.
resultsFunded awards most frequently considered the prevention (n = 6) and treatment (n = 8) phases of the cancer control continuum, with few focusing on other phases of the continuum. Study samples were racially heterogeneous and often socioeconomically challenged, but no grants focused on other high-risk populations such as individuals with disabilities. Stigma was most often assessed as a predictor (n = 10) and measured at the individual level (n = 16). Seven awards assessed both HIV and cancer stigma, but these constructs were usually assessed independently. Only three grants included an intervention component addressing stigma.
conclusionNCI-supported research on stigma in the context of HIV and cancer has been limited over the past decade. Results point to opportunities for enhancing extramural research in this area, including developing and testing stigma reduction interventions, expanding research across the cancer control continuum, and focusing on all affected populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.